These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9480144)

  • 1. [Post-transfusional platelet increment: effect of clinical factors].
    Muggenthaler KH; Böck M; Heim MU; Mempel W
    Beitr Infusionsther Transfusionsmed; 1994; 32():467-9. PubMed ID: 9480144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Post-transfusion rise in thrombocytes: observations in a hematologic-oncologic patient sample].
    Böck M; Muggenthaler KH; Schmidt U; Heim MU; Mempel W
    Infusionsther Transfusionsmed; 1995 Dec; 22(6):350-4. PubMed ID: 8589595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet transfusion therapy.
    Slichter SJ
    Hematol Oncol Clin North Am; 2007 Aug; 21(4):697-729, vii. PubMed ID: 17666286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of antibiotics on posttransfusion platelet increment.
    Böck M; Muggenthaler KH; Schmidt U; Heim MU
    Transfusion; 1996; 36(11-12):952-4. PubMed ID: 8937402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the effectiveness of whole blood-derived platelets stored as a pool: a randomized block noninferiority trial.
    Heddle NM; Cook RJ; Blajchman MA; Barty RL; Sigouin CS; Boye DM; Nelson EJ; Kelton JG
    Transfusion; 2005 Jun; 45(6):896-903. PubMed ID: 15934987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet function testing to assess effectiveness of platelet transfusion therapy.
    Salama ME; Raman S; Drew MJ; Abdel-Raheem M; Mahmood MN
    Transfus Apher Sci; 2004 Apr; 30(2):93-100. PubMed ID: 15062745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet transfusion refractoriness.
    Hod E; Schwartz J
    Br J Haematol; 2008 Jul; 142(3):348-60. PubMed ID: 18510692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calculated platelet dose: Is it useful in clinical practice?
    Askari S; Weik PR; Crosson J
    J Clin Apher; 2002; 17(2):103-5. PubMed ID: 12210715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ABO blood groups and platelet transfusion].
    Eckstein R; Zeiler T; Zingsem J; Heuft HG; Musch R; Weisbach V
    Beitr Infusionsther; 1990; 26():157-9. PubMed ID: 1703819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryopreserved autologous platelet transfusions in alloimmunized patients with acute leukemia.
    Wiesneth M; Koerner K; Funke I; Seifried E; Cardoso M; Heimpel H; Kubanek B
    Beitr Infusionsther; 1992; 30():297-300. PubMed ID: 1284720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet alloimmunization in multitransfused patients with haemato-oncological disorders.
    Bajpai M; Kaura B; Marwaha N; Kumari S; Sharma RR; Agnihotri SK
    Natl Med J India; 2005; 18(3):134-6. PubMed ID: 16130614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing platelet transfusion therapy.
    Heal JM; Blumberg N
    Blood Rev; 2004 Sep; 18(3):149-65. PubMed ID: 15183900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
    Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
    Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower or higher doses for prophylactic platelet transfusions: results of a meta-analysis of randomized controlled trials.
    Cid J; Lozano M
    Transfusion; 2007 Mar; 47(3):464-70. PubMed ID: 17319827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune and nonimmune causes of low recovery from leukodepleted platelet transfusions: a prospective study.
    Levin MD; de Veld JC; van der Holt B; van 't Veer MB
    Ann Hematol; 2003 Jun; 82(6):357-62. PubMed ID: 12719885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation.
    Gurkan E; Patah PA; Saliba RM; Ramos CA; Anderson BS; Champlin R; de Lima M; Lichtiger B
    Bone Marrow Transplant; 2007 Sep; 40(5):461-4. PubMed ID: 17589530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of crossmatch tests and panel tests as a screening tool to predict the outcome of platelet transfusion in a non-selected haematological population of patients.
    Levin MD; van der Holt B; de Veld JC; Gratama JW; de Vries W; van't Veer MB
    Vox Sang; 2004 Nov; 87(4):291-8. PubMed ID: 15585026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient and product factors affecting platelet transfusion results.
    Heim D; Passweg J; Gregor M; Buser A; Theocharides A; Arber C; Meyer-Monard S; Halter J; Tichelli A; Gratwohl A
    Transfusion; 2008 Apr; 48(4):681-7. PubMed ID: 18208413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effect of buffy-coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy.
    Akkök CA; Brinch L; Lauritzsen GF; Solheim BG; Kjeldsen-Kragh J
    Vox Sang; 2007 Jul; 93(1):42-8. PubMed ID: 17547564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of transfusion of prestorage-leukoreduced apheresis platelets.
    Ogawa Y; Wakana M; Tanaka K; Oka K; Aso H; Hayashi M; Seno T; Ishida T; Nomura S; Fukuhara S
    Vox Sang; 1998; 75(2):103-9. PubMed ID: 9784662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.